Intravenous iron dextran in clinical medicine

R. D. Hamstra, M. H. Block and A. L. Schocket

Four hundred seventy-one adult patients and ten adult prisoner volunteers received 2,099 intravenous (IV) injections of iron dextran (Imferon), usually 250 to 500 mg at less than 100 mg/min. Intravenous iron supplies enough iron to permit RBC formation greater than 50 mL/day and repletion of tissue iron. Tissue iron did not always supply iron at an optimal rate. Hemoglobin production was higher after IV than oral or intramuscular iron if the hemoglobin level was less than 9 g/dL. Three life-threatening immediate anaphylactoid and eight severe delayed reactions were observed. There were no deaths. Delayed reactions were more frequent in women and collagen-vascular diseases and less frequent in pregnancy. Because anaphylactoid reactions are serious and unpredictable, IV iron dextran should be used only when iron deficiency anemia cannot be treated adequately with oral iron.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ferumoxytol for Treating Iron Deficiency Anemia in CKD
Spinowitz et al.
J. Am. Soc. Nephrol. 2008;19:1599-1605.
ABSTRACT | FULL TEXT  

Acute Injury with Intravenous Iron and Concerns Regarding Long-Term Safety
Bishu and Agarwal
CJASN 2006;1:S19-S23.
ABSTRACT | FULL TEXT  

Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients
Walters and Van Wyck
Nephrol Dial Transplant 2005;20:1438-1442.
ABSTRACT | FULL TEXT  

Hypersensitivity reactions and deaths associated with intravenous iron preparations
Bailie et al.
Nephrol Dial Transplant 2005;20:1443-1449.
ABSTRACT | FULL TEXT  

Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols
Aronoff
J. Am. Soc. Nephrol. 2004;15:S99-S106.
FULL TEXT  

On the relative safety of parenteral iron formulations
Chertow et al.
Nephrol Dial Transplant 2004;19:1571-1575.
ABSTRACT | FULL TEXT  

Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety
Michael et al.
Nephrol Dial Transplant 2004;19:1576-1580.
ABSTRACT | FULL TEXT  

Intramuscular administration of iron dextran is inappropriate for treatment of moderate pregnancy anemia, both in intervention research on underprivileged women and in routine prenatal care provided by public health services
Solomons and Schumann
Am. J. Clin. Nutr. 2004;79:1-3.
FULL TEXT  

A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women
Sharma et al.
Am. J. Clin. Nutr. 2004;79:116-122.
ABSTRACT | FULL TEXT  

Is iron gluconate really safer than iron dextran?
Eichbaum et al.
Blood 2003;101:3756-3756.
FULL TEXT  

A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer(R)) vs iron gluconate (Ferrlecit(R)) in haemodialysis patients treated with rHuEpo
Kosch et al.
Nephrol Dial Transplant 2001;16:1239-1244.
ABSTRACT | FULL TEXT  

Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen?
Macdougall
Nephrol Dial Transplant 2000;15:1743-1745.
FULL TEXT  

Erythropoietin, iron, and erythropoiesis
Goodnough et al.
Blood 2000;96:823-833.
ABSTRACT | FULL TEXT  

Is there material hazard to treatment with intravenous iron?
Fishbane et al.
Nephrol Dial Transplant 1999;14:2595-2598.
FULL TEXT